Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Does the Forecast Indicate for the Intratumoral Cancer Therapies Market From 2025 to 2029?
The market size for intratumoral cancer treatments has seen a swift escalation in the past few years. It is forecasted to accelerate from a value of $140 billion in 2024 to $156.96 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.1%. This substantial growth during the historical timeframe can be linked to factors such as progression in cancer research, a rise in cancer cases, the rising need for precision medicine, clinical research and initiatives, and existing unmet medical needs.
Projected to expand rapidly in the coming years, the market for intratumoral cancer therapies is anticipated to reach “$243.95 billion by 2029, accelerating at a compound annual growth rate (CAGR) of 11.7%. Several factors, including advances in immunotherapy, a surge in precision medicine adoption, expansion of clinical trials, heightened attention to rare cancers, and regulatory support and clearance, contribute to the expected growth within the forecast period. The period will likely witness emerging trends such as the study of intratumoral immunomodulators, the incorporation of image-guided therapies, the application of hyperthermia in intratumoral treatments, clinical trials probing combination therapies, and regulatory backing for intratumoral therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9979&type=smp
What Elements Are Contributing To Growth In The Intratumoral Cancer Therapies Market?
The rise in cancer cases is anticipated to drive the expansion of the intratumoral cancer therapies market. Cancer, defined by the uncontrolled multiplication and dissemination of abnormal cells, is a collective term for various diseases. Intratumoral cancer therapies aid in the detection and treatment of cancer, minimizing off-target toxicities, dose-limiting toxicities, and undesirable immune stimulation side effects in cancer patients. As an example, the American Cancer Society, a US-based non-profit cancer advocacy group, reported in January 2023 that cancer incidents escalated to 1,958,310 in 2023, which signifies a 3.16% increase from 1,898,160 cases in 2021. Consequently, the surge in cancer prevalence is propelling the expansion of the intratumoral cancer therapies market.
Which Segments Are Detailed In The Global Intratumoral Cancer Therapies Market Report?
The intratumoral cancer therapies market covered in this report is segmented –
1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines
2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications
3) By End Users: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors
4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy
5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists
6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)
7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)
What Trends Are Currently Influencing Growth In The Intratumoral Cancer Therapies Market?
Technological advancements are emerging as a major trend in the intratumoral cancer treatments market. To maintain a competitive edge, firms in this market are resorting to novel technologies. For example, in March 2022, Evonik, an American specialty chemical manufacturing firm, introduced a unique microparticle technology known as EUDRATEC SoluFlow. This invention aims to enhance the solubility of active medicinal elements in oral drug formulations used in cancer treatments. This revolutionary technology enables the use of chemicals, previously considered insoluble, in the development of a broader range of oral medications.
Who Are The Key Contributors To Growth In The Intratumoral Cancer Therapies Market?
Major companies operating in the intratumoral cancer therapies market include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Dechra Pharmaceuticals PLC, Torigen Pharmaceuticals Inc., Elekta, Virbac, Norbrook Laboratories, Regeneus Ltd., QBiotics Group, VetDC
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report
Which Region Is Projected To Lead The Intratumoral Cancer Therapies Market By 2025?
North America was the largest region in the intratumoral cancer therapies market in 2024. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9979&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model